OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 56 WORKING AT THE INTERSECTION OF TECHNOLOGY AND WELL-BEING BIOGEN 2021 YEAR IN REVIEW Biogen launches neurotechprize, a global challenge for aging societies In partnership with EIT Health, Biogen Germany launched neurotechprize, a call for applicants with the most promising solutions and technologies to help address the challenge of Alzheimer’s disease in Germany and beyond. The submission process, closed in December 2021, received a total of 79 applicants from 23 countries. The winners will be announced in 2022. Transforming the way we assess neurological diseases with Konectom™ Traditional clinical outcome measurements are limited in their ability to assess and monitor the true evolution of neurological diseases. Most rely on subjective, insensitive and infrequent assessments. High-field MRI suggests that disease evolution is not well captured. For example, in MS, in 70-90% of people where we see brain lesion evolution, we see no change in clinical assessments. Emerging digital measurement solutions, such as Biogen’s proprietary digital measurement platform Konectom™, leverage wearable sensors, digital biomarkers and patient empowerment to improve how we assess and monitor neurological diseases. Konectom can assess key neurological functions such as cognition, fine and gross motor control, walking and mobility in clinical studies, in-clinic or remotely. In 2021, Konectom was officially CE-marked as a Class 1 Medical Device, meaning it passed all regulatory and quality steps of development and affirmed conformity with EU Medical Devices Regulations. Konectom can now be distributed in Biogen’s clinical studies in the EU to support clinical development and real-world evidence generation in MS. SPOTLIGHT Biogen Spain honored for innovative products and services For the second year in a row, Biogen Spain has been named a winner of Actualidad Economica’s 100 Best Ideas Awards, highlighting innovative products and services. Biogen’s Cleo app, which is used by 3,300 MS patients in Spain, was recognized in the Mobile Technology category. This award, along with last year’s recognition of CogEval, reinforces Biogen’s position as an innovative company, not only in our therapies, but also in the services we offer to the patient community and HCPs. Cleo/Aby voted #1 MS app and available in 17 countries Cleo (Aby in North America), our digital disease companion app to help people who live with MS, is available in 17 countries worldwide, reaching over 600,000 users. According to a Pascaleo Survey in November 2021, Cleo was ranked the #1 MS app by over 650 neurologists in 10 countries. In France, Cleo joined the digital healthcare space (Mon espace santé), a dedicated platform for French healthcare system users with access to a Digital Health Store that provides a catalog of mobile applications and websites. Neurodiem voted preferred neurology website Neurodiem, our independent information platform for healthcare professionals in neurology, has been voted the #1 preferred online platform dedicated to the specialty. This was according to a Pascaleo survey of 650+ neurologists in 10 countries performed in November 2021. With more than 20,000 neurologists registered worldwide and over 1 million visits, the platform is now available in 27 countries and on five continents.